322 related articles for article (PubMed ID: 19176796)
1. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.
Provenzano R; Schiller B; Rao M; Coyne D; Brenner L; Pereira BJ
Clin J Am Soc Nephrol; 2009 Feb; 4(2):386-93. PubMed ID: 19176796
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
[TBL] [Abstract][Full Text] [Related]
3. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.
Lu M; Cohen MH; Rieves D; Pazdur R
Am J Hematol; 2010 May; 85(5):315-9. PubMed ID: 20201089
[TBL] [Abstract][Full Text] [Related]
4. Ferumoxytol for treating iron deficiency anemia in CKD.
Spinowitz BS; Kausz AT; Baptista J; Noble SD; Sothinathan R; Bernardo MV; Brenner L; Pereira BJ
J Am Soc Nephrol; 2008 Aug; 19(8):1599-605. PubMed ID: 18525001
[TBL] [Abstract][Full Text] [Related]
5. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
.
Macdougall IC; Strauss WE; Dahl NV; Bernard K; Li Z
Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204
[TBL] [Abstract][Full Text] [Related]
6. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease.
Schwenk MH
Pharmacotherapy; 2010 Jan; 30(1):70-9. PubMed ID: 20030475
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.
Schiller B; Bhat P; Sharma A
Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802
[TBL] [Abstract][Full Text] [Related]
8. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients.
Fishbane S; Bolton WK; Winkelmayer WC; Strauss W; Li Z; Pereira BJ
Clin Nephrol; 2012 Sep; 78(3):181-8. PubMed ID: 22874106
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients.
Spinowitz BS; Schwenk MH; Jacobs PM; Bolton WK; Kaplan MR; Charytan C; Galler M
Kidney Int; 2005 Oct; 68(4):1801-7. PubMed ID: 16164657
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron.
Vadhan-Raj S; Strauss W; Ford D; Bernard K; Boccia R; Li J; Allen LF
Am J Hematol; 2014 Jan; 89(1):7-12. PubMed ID: 23983177
[TBL] [Abstract][Full Text] [Related]
12. Iron indices and intravenous ferumoxytol: time to steady-state.
Kapoian T; O'Mara NB; Carreon M; Gajary A; Rizkala A; Lefavour G; Sherman RA; Walker J
Ann Pharmacother; 2012 Oct; 46(10):1308-14. PubMed ID: 22968523
[TBL] [Abstract][Full Text] [Related]
13. Intravenous infusions of ferumoxytol compared to oral ferrous sulfate for the treatment of anemia in pregnancy: a randomized controlled trial.
Awomolo AM; McWhirter A; Sadler LC; Coppola LM; Hill MG
Am J Obstet Gynecol MFM; 2023 Sep; 5(9):101064. PubMed ID: 37348816
[TBL] [Abstract][Full Text] [Related]
14. Neonatal outcomes from a randomized controlled trial of maternal treatment of iron deficiency anemia with intravenous ferumoxytol vs oral ferrous sulfate.
Awomolo AM; McWhirter A; Sadler LC; Coppola LM; Hill MG
Am J Obstet Gynecol MFM; 2023 Sep; 5(9):101063. PubMed ID: 37348817
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis.
Charytan C; Qunibi W; Bailie GR;
Nephron Clin Pract; 2005; 100(3):c55-62. PubMed ID: 15824508
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min.
Auerbach M; Strauss W; Auerbach S; Rineer S; Bahrain H
Am J Hematol; 2013 Nov; 88(11):944-7. PubMed ID: 23828252
[TBL] [Abstract][Full Text] [Related]
17. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy.
Hetzel D; Strauss W; Bernard K; Li Z; Urboniene A; Allen LF
Am J Hematol; 2014 Jun; 89(6):646-50. PubMed ID: 24639149
[TBL] [Abstract][Full Text] [Related]
18. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
19. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?
Stancu S; Bârsan L; Stanciu A; Mircescu G
Clin J Am Soc Nephrol; 2010 Mar; 5(3):409-16. PubMed ID: 20019121
[TBL] [Abstract][Full Text] [Related]
20. Safety of ferumoxytol in patients with anemia and CKD.
Singh A; Patel T; Hertel J; Bernardo M; Kausz A; Brenner L
Am J Kidney Dis; 2008 Nov; 52(5):907-15. PubMed ID: 18824288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
